Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOARGYS vs DEMULEN 1/50-21
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LOARGYS is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.
DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Acute gouty arthritis,Dysmenorrhea,Management of acute pain
Prevention of pregnancy,Treatment of moderate acne vulgaris (off-label use)
100 mg orally twice daily.
1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.
Terminal elimination half-life: 12-18 hours (prolonged in renal impairment).
Ethinylestradiol: 13 ± 3 h (biphasic; terminal phase used for dosing interval). Clinical context: steady-state achieved after ~3 days; missed dose may reduce contraceptive efficacy if >36 h.
Hepatic metabolism primarily via cytochrome P450 enzymes, including CYP2C9; formation of inactive metabolites, with less than 1% excreted unchanged in urine.
Ethinyl estradiol undergoes first-pass metabolism in the gut wall and liver, with hydroxylation by CYP3A4 and conjugation via glucuronidation and sulfation. Ethynodiol diacetate is rapidly deacetylated to norethindrone, which is metabolized by reduction and conjugation, with CYP3A4 as a minor pathway.
Primarily renal (70-80% unchanged; 10-15% as metabolites); biliary/fecal (5-10%).
Renal (approx. 50% as metabolites, <1% unchanged), fecal (approx. 40%, largely as ethinylestradiol conjugates), biliary (minor, enterohepatic recirculation of ethinylestradiol)
85-90% (primarily albumin).
Ethinylestradiol: 97-98% bound to serum albumin (primarily) and SHBG; ethynodiol diacetate: >95% bound to albumin and SHBG.
0.5-0.7 L/kg (indicates moderate tissue distribution).
Ethinylestradiol: 2.8-4.3 L/kg (extensive tissue distribution, including breast and reproductive tissues); ethynodiol: 1.5-2.0 L/kg.
Oral: 60-70% (first-pass metabolism).
Oral: Ethinylestradiol 38-48% (first-pass metabolism); ethynodiol diacetate ~60% (rapid hydrolysis to active norethindrone).
GFR 30-59 m L/min: 75 mg twice daily; GFR 15-29 m L/min: 50 mg twice daily; GFR <15 m L/min: not recommended.
No dose adjustment required for mild-moderate renal impairment. Avoid use in severe renal impairment or dialysis due to potential fluid retention and electrolyte disturbances.
Child-Pugh A: no adjustment; Child-Pugh B: 75 mg twice daily; Child-Pugh C: not recommended.
Contraindicated in acute or chronic hepatic dysfunction, including Child-Pugh class A, B, or C. Use in mild hepatic impairment not recommended.
Not established; safety and efficacy not studied in patients <18 years.
Not indicated for use before menarche. For post-menarcheal adolescents, same dosing as adults. Safety and efficacy established in post-pubertal females.
No specific dose adjustment required; monitor renal function and adjust based on GFR.
Not indicated after menopause. Risk of thromboembolic events outweighs benefits in women over 35 who smoke or have cardiovascular risk factors.
Cardiovascular thrombotic events: NSAIDs, including LOARGYS, increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. The risk is higher in patients with cardiovascular disease or risk factors. LOARGYS is contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age and with the number of cigarettes smoked, and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Cardiovascular thrombotic events,Gastrointestinal adverse events (bleeding, ulceration, perforation),Hypertension and exacerbation of hypertension,Renal effects: renal papillary necrosis, interstitial nephritis, and acute renal failure,Hepatic effects: elevations of liver enzymes, severe hepatic reactions,Anaphylactic reactions,Serious skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis,Fluid retention and edema,Masking of inflammation and fever
Increased risk of thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking increases cardiovascular risk, especially in women over 35,Increased risk of hypertension, gallbladder disease, and hepatic neoplasia,Risk of retinal thrombosis; discontinue if unexplained vision loss occurs,May cause fluid retention; use with caution in conditions affected by fluid retention,May induce cholestatic jaundice; discontinue if jaundice develops,May cause carbohydrate and lipid metabolism changes
Hypersensitivity to LOARGYS or any component of the formulation,History of asthma, urticaria, or allergic-type reaction after taking aspirin or other NSAIDs,Patients with active gastrointestinal bleeding, peptic ulcer disease, or perforation,Advanced renal disease,Treatment of perioperative pain in the setting of CABG surgery,Patients with severe heart failure (NYHA Class IV)
Known or suspected pregnancy,Current or past history of thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma,Active liver disease (e.g., acute viral hepatitis, decompensated cirrhosis),Hypersensitivity to any component
Avoid high-potassium foods (e.g., bananas, oranges, tomatoes) if taking with potassium-sparing diuretics or in renal impairment. Grapefruit juice may alter drug metabolism; limit intake.
No specific food interactions. Oral contraceptives may increase caffeine levels; limit caffeine intake if side effects like jitteriness occur. Grapefruit and grapefruit juice do not significantly affect this medication.
FDA Pregnancy Category X. First trimester: high risk of major congenital malformations (e.g., craniofacial defects, neural tube defects). Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and neonatal renal impairment.
First trimester: Use contraindicated due to increased risk of congenital anomalies, particularly cardiovascular defects and limb reduction defects, associated with sex hormones. Second and third trimesters: Avoid due to risk of fetal harm, including masculinization of female fetus with progestins; also associated with increased risk of neonatal jaundice and liver dysfunction.
Contraindicated during breastfeeding. Excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants.
Small amounts of ethinyl estradiol and ethynodiol diacetate are excreted in breast milk. M/P ratio not established. Estrogen-progestin combinations may reduce milk production and alter milk composition; use during breastfeeding is generally not recommended. Consider alternative contraception.
Avoid use during pregnancy due to teratogenicity; no dose adjustment guidelines exist as drug is contraindicated.
Not applicable as use is contraindicated during pregnancy. No pharmacokinetic studies have been conducted to recommend dose adjustments.
LOARGYS is an angiotensin II receptor blocker (ARB) indicated for hypertension. Avoid in pregnancy (Pregnancy Category D). Monitor serum potassium and renal function periodically. May cause dizziness; advise caution with driving. Combination with NSAIDs may reduce antihypertensive effect and increase renal risk.
DEMULEN 1/50-21 is a monophasic oral contraceptive containing ethinyl estradiol 50 mcg and ethynodiol diacetate 1 mg. Use with caution in patients over 35 who smoke due to increased cardiovascular risk. Monitor for breakthrough bleeding, especially in the first three cycles. Consider drug interactions with rifampin, anticonvulsants, and broad-spectrum antibiotics. Administer at the same time daily to maintain efficacy. The 21-day regimen requires a 7-day pill-free interval. Instruct to start on first day of menses or first Sunday after onset.
Take exactly as prescribed, usually once daily.,Avoid salt substitutes containing potassium unless approved by doctor.,Do not stop taking without consulting your doctor.,Report symptoms like lightheadedness, fainting, or swelling.,Use effective contraception during treatment; not safe in pregnancy.
Take one tablet daily at the same time, starting on the first day of your menstrual period or the first Sunday after your period begins.,Swallow tablet whole with water, with or without food.,After finishing all 21 tablets, wait 7 days before starting a new pack. You will have a withdrawal bleed during this time.,If you miss a tablet by less than 12 hours, take it immediately. If more than 12 hours, take the missed tablet and use backup contraception for 7 days.,Seek emergency medical care for symptoms of blood clots (sudden severe headache, chest pain, shortness of breath, leg pain/swelling), stroke (sudden numbness/weakness, slurred speech), or liver problems (yellowing skin/eyes, dark urine).,Avoid smoking while taking this medication, especially if over age 35, due to increased risk of cardiovascular events.,Inform your healthcare provider about all other medications (including over-the-counter drugs, herbal supplements like St. John's Wort) as they may reduce contraceptive efficacy.,This medication does not protect against HIV or other sexually transmitted infections.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOARGYS vs DEMULEN 1/50-21, answered by our medical review team.
LOARGYS is a Combination Oral Contraceptive that works by LOARGYS is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing the synthesis of prostaglandins involved in inflammation, pain, and fever.. DEMULEN 1/50-21 is a Combination Oral Contraceptive that works by DEMULEN 1/50-21 is a combined oral contraceptive containing ethinyl estradiol and ethynodiol diacetate. Ethinyl estradiol and progestins inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation. Progestins also increase cervical mucus viscosity and alter endometrial receptivity, impeding sperm penetration and implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOARGYS and DEMULEN 1/50-21 depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOARGYS is: 100 mg orally twice daily.. The standard adult dose of DEMULEN 1/50-21 is: 1 tablet (ethinyl estradiol 50 mcg, norethindrone 1 mg) orally once daily for 21 days, followed by 7 days off.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOARGYS and DEMULEN 1/50-21 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOARGYS is classified as Category C. FDA Pregnancy Category X. First trimester: high risk of major congenital malformations (e.g., craniofacial defects, neural tube defects). Second and third trimesters: risk of fetal. DEMULEN 1/50-21 is classified as Category C. First trimester: Use contraindicated due to increased risk of congenital anomalies, particularly cardiovascular defects and limb reduction defects, associated with sex hormones. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.